Hypertension, angiotensin II, aldosterone, and race

Journal of the American College of Cardiology

Volumn 41, Issue 7, 2003, Pages 1156-1158

  Ben Yehuda, Ori ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; EDITORIAL; GYNECOMASTIA; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; LOW DRUG DOSE; MASTALGIA; MONOTHERAPY; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; PLASMA RENIN ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SOCIAL ASPECT; SYSTOLIC BLOOD PRESSURE; VAGINA BLEEDING;

EID: 0037414071     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00053-6     Document Type: Editorial

References (23)

1. The Sixth Report of the Joint National Committee on Prevention Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-6.
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the U.S. adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-13.
3. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 1982;306:1276-9.
4. Coresh J, Jaar B. Further trends in the etiology of end-stage renal disease in African-Americans. Curr Opin Nephrol Hypertens 1997;6:243-9.
5. Flack JM, Oparil S, Pratt HJ, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol 2003;41:1148-55.
6. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
7. Stier CT, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002;10:97-107.
8. Jorde UP, Vittorio T, Katz SD, et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106:1055-7.
9. Li S, Wu P, Zhong S, et al. Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular aldosterone. Horm Res 2001;55:293-7.
10. Moser M, Lunn J. Responses to captopril and hydrochlorothiazide in black patients with hypertension. Clin Pharmacol Ther 1982;32:307-12.
11. Flack JM, Saunders E, Gradman M, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001;23:1193-208.
12. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:1004-10.
13. Ferrario CM, Flack JM. Pathologic consequences of increased angiotensin II activity. Cardiovasc Drugs Ther 1996;10:511-18.
14. Schiffrin EL, Park JB, Intengnan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-9.
15. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000;101:1586-93.
16. Levy SB, Talner LB, Coel MN, et al. Renal vasculature in essential hypertension: racial differences. Ann Intern Med 1978;88:12-16.
17. Lindholm LH, Ibsen I, Dahlof B, et al. Diabetes in the Losartan Intervention for End point reduction in hypertension study (LIFE). Presented at the 19th Scientific Meeting of the International Society of Hypertension/12th European Meeting on Hypertension. Prague, Czech Republic: June 2002.
18. Product insert. Inspra (eplerenone tablets). Pharmacia Corp. 2002.
19. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408-11.
20. Schwartz RS. Racial profiling in medical research. N Engl J Med 2001;344:1392-3.
21. 2c-adrenergic receptors and the risk of heart failure. N Engl J Med 2002;347:1135-42.
22. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65.
23. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.